Together, these changes suggest that PB impacts inhibitory neurotransmission, and raise the possibility that these changes could in turn, impact PB efficacy–reduced parvalbumin neurons, for example, would be expected to worsen epilepsy outcomes. The gene discussed is PVALB; the disease is epilepsy.